SBK Financial
COGT icon

SBK Financial’s Cogent Biosciences COGT Stock Holding History

SBK Financial’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.6K Hold
300
– – ﹤0.01% 169
2026
Q2 		$11.6K Buy
+300
New +$10.5K 0.01% 182

Other funds holding COGT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

SBK Financial's COGT Position: Q3 2026 in Review

SBK Financial held its Cogent Biosciences (COGT) position steady in Q3 2026 at 300 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #169.

SBK Financial first reported a position in COGT in Q2 2026 and has held it in 2 quarters since. The position peaked at $11.6K in Q2 2026. 99 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • SBK Financial held 300 shares of Cogent Biosciences worth $9.6K as of Q3 2026.
  • SBK Financial left its Cogent Biosciences share count unchanged in Q3 2026.
  • Cogent Biosciences made up ﹤0.01% of SBK Financial's portfolio in Q3 2026, its #169 holding.
  • SBK Financial first reported a position in Cogent Biosciences in Q2 2026 and has held it in 2 quarters since.
  • SBK Financial's Cogent Biosciences position peaked at $11.6K in Q2 2026.
  • 99 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on SBK Financial's 13F filing for Q3 2026, filed 2 Nov 2026.